; on behalf of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee Disclaimer: These ACMG standards and guidelines are developed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these standards and guidelines is voluntary and does not necessarily ensure a successful medical outcome. These standards and guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these standards and guidelines. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.
6.5.2
The laboratory director and staff should be familiar with the chromosomal and molecular aberrations associated with tumor types/subtypes and their clinical significance. Supplementary Tables S1-S5 online include common solid  tumor and lymphoma chromosomal aberrations with known  genes, potential FISH targets, clinical significance, and references. 6.5.3 Pediatric tumors should be cytogenetically analyzed whenever sufficient fresh tissue is available. Karyotyping, although low-resolution, provides a view of the entire genome. This genome view allows detection of cytogenetic aberrations that are commonly disease-or disease subtype-specific and have prognostic and therapeutic significance. Genetic analysis of adult tumors is indicated whenever such analysis may provide diagnostic, prognostic, or treatment-related information, especially if targeted therapies are available for the disorder undergoing study.
6.5.4 Methods for the processing of tumor material should be determined by the cytogenetic laboratory based on available clinical and pathologic findings. Laboratories should work with the oncologist and pathologist to determine the method(s) to gain the most genetic information cost-effectively. The laboratory should seek information about the suspected diagnosis and tissue type at the time of sample receipt to choose the most appropriate testing and tissue culture method(s) and to determine if DNA should be isolated from the fresh tumor. Supplementary Table S6 online provides tumor nomenclature for tumor culture method selection. 6.5.5 Conventional cytogenetic, FISH, CMA, gene mutation panel, or sequencing analysis may be used as a primary or secondary method of evaluation of the tumor tissue. Multiple technologies may be needed for specific tumor types. The availability of fresh tissue, the differential diagnosis, a need for rapid diagnostic information, and the type of information needed should be used to prioritize testing such as conventional cytogenetic analysis, FISH, CMA, and/or mutation analysis.
6.5.6 Cytogenetic and molecular analysis results must be interpreted within the context of the pathologic and clinical findings. 6.5.7 For quality assurance, the laboratory may monitor the number and types of tumors received, the percentage of tumors with abnormal results, the cell culture success rate, and the success rate for FISH and CMA studies.
6.5.8 The presence or absence of specific aberrations should be available to the physician as soon as is feasible to contribute to the patient's plan of care. If the sample is to be processed for CMA or sequencing, select a portion of the sample for DNA isolation. If the sample is for FISH analysis, touch preparations may be made or direct harvest performed. If the sample is for chromosome analysis, tissue culture will be required.
SAMPLE COLLECTION AND PROCESSING
6.6.2.2 The fresh tumor sample should be inspected and details of the sample size, color, and attributes recorded. The time of sample collection and the time of sample receipt in the laboratory should be documented.
6.6.2.3 The cytogenetics laboratory should expect the sample submitted by a pathologist to be most representative of the tumor as determined by gross examination. However, if the fresh sample received by the laboratory is large and appears heterogeneous, portions of the sample may be cultured separately. If obvious normal, necrotic, or vascular tissues are present, the tumor should be separated from nontumor tissue for processing. Obvious necrotic tissue should be removed to reduce enzymatic damage induced by dying cells. If the tumor cannot be distinguished from normal or necrotic tissue, caution should be exercised and the entire sample processed.
6.6.2.4 For tissues from a body region with high concentrations of bacteria (e.g., tonsils, gut), treatment of the sample prior to disaggregation with antibiotic and/or antifungal solutions and addition of antibiotic and/or antifungals to the medium may be prudent. a. The diagnosis and histopathology of a tumor can be helpful in determining culture and harvest methods. Different cell types can be expected to respond differently with growth medium, harvest method, and other factors (Table 6) . If the diagnosis is unknown at culture initiation, it can be helpful to know whether the pathologist would classify the tumor as a "small round cell tumor" (SRCT), which includes lymphoproliferative disorders. SRCTs can be successfully grown in suspension, whereas non-SRCTs are best grown with monolayer (flask or coverslip) culture methods. Most, but not all, SRCTs (e.g., lymphoproliferative disorders) will also grow in monolayer culture. a. As a primary method for tumor evaluation, FISH is useful when (i) fresh tumor tissue is not available; (ii) rapid diagnostic information is needed to narrow the differential diagnosis; (iii) gene amplification or rearrangement for diagnostic or prognostic and/or therapeutic purposes is to be determined; (iv) no metaphase cells are obtained by culture of tumor material; or (v) conventional cytogenetic analysis yields a normal result. b. Supplemental FISH may be used as an adjunct to the initial conventional chromosomal analysis or CMA analysis to: (i) document a specific molecular event (e.g., gene rearrangement or fusion); (ii) provide a rapid result to aid in the differential diagnosis or planning of therapy; (iii) to assess gene copy number,; (iv) clarify level of clonality; or (v) confirm a microarray variant.
c. Follow-up FISH studies may be indicated to assess recurrent disease or disease progression and/or to differentiate recurrence of a tumor from a new disease process. i. If initial studies failed to identify the clonal process unique to the tumor, then follow-up studies may provide another opportunity. 
